Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling.

Jung KY, Samadani R, Chauhan J, Nevels K, Yap JL, Zhang J, Worlikar S, Lanning ME, Chen L, Ensey M, Shukla S, Salmo R, Heinzl G, Gordon C, Dukes T, MacKerell AD Jr, Shapiro P, Fletcher S.

Org Biomol Chem. 2013 Jun 14;11(22):3706-32. doi: 10.1039/c3ob40199e.

2.

3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization.

Liu K, Rao W, Parikh H, Li Q, Guo TL, Grant S, Kellogg GE, Zhang S.

Eur J Med Chem. 2012 Jan;47(1):125-37. doi: 10.1016/j.ejmech.2011.10.031. Epub 2011 Oct 21.

PMID:
22074985
3.

New diarylamides and diarylureas possessing 8-amino(acetamido)quinoline scaffold: synthesis, antiproliferative activities against melanoma cell lines, kinase inhibition, and in silico studies.

Koh EJ, El-Gamal MI, Oh CH, Lee SH, Sim T, Kim G, Choi HS, Hong JH, Lee SG, Yoo KH.

Eur J Med Chem. 2013;70:10-21. doi: 10.1016/j.ejmech.2013.06.060. Epub 2013 Aug 9.

PMID:
24128410
4.

New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: Synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies.

Choi WK, El-Gamal MI, Choi HS, Baek D, Oh CH.

Eur J Med Chem. 2011 Dec;46(12):5754-62. doi: 10.1016/j.ejmech.2011.08.013. Epub 2011 Aug 12.

PMID:
22014559
5.

Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways.

Li Q, Wu J, Zheng H, Liu K, Guo TL, Liu Y, Eblen ST, Grant S, Zhang S.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4526-30. doi: 10.1016/j.bmcl.2010.06.030. Epub 2010 Jun 8.

PMID:
20580230
7.

Anticancer activity of novel hybrid molecules containing 5-benzylidene thiazolidine-2,4-dione.

Romagnoli R, Baraldi PG, Salvador MK, Camacho ME, Balzarini J, Bermejo J, Estévez F.

Eur J Med Chem. 2013 May;63:544-57. doi: 10.1016/j.ejmech.2013.02.030. Epub 2013 Mar 14.

PMID:
23537942
8.

Thiazolidine-2,4-diones: progress towards multifarious applications.

Jain VS, Vora DK, Ramaa CS.

Bioorg Med Chem. 2013 Apr 1;21(7):1599-620. doi: 10.1016/j.bmc.2013.01.029. Epub 2013 Jan 24. Review.

PMID:
23419324
9.

7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel synthetic compound induces lung carcinoma cell death associated with inhibiting ERK and CDC2 phosphorylation via a p53-independent pathway.

Hsu TS, Chen C, Lee PT, Chiu SJ, Liu HF, Tsai CC, Chao JI.

Cancer Chemother Pharmacol. 2008 Oct;62(5):799-808. doi: 10.1007/s00280-007-0667-5. Epub 2008 Jan 10. Erratum in: Cancer Chemother Pharmacol. 2008 Oct;62(5):809.

PMID:
18193228
10.

Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: development of potential substrate-specific ERK1/2 inhibitors.

Li Q, Al-Ayoubi A, Guo T, Zheng H, Sarkar A, Nguyen T, Eblen ST, Grant S, Kellogg GE, Zhang S.

Bioorg Med Chem Lett. 2009 Nov 1;19(21):6042-6. doi: 10.1016/j.bmcl.2009.09.057. Epub 2009 Sep 18.

PMID:
19796943
11.

Discovery and SAR of thiazolidine-2,4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening.

Liu X, Xie H, Luo C, Tong L, Wang Y, Peng T, Ding J, Jiang H, Li H.

J Med Chem. 2010 Mar 25;53(6):2661-5. doi: 10.1021/jm901798e.

PMID:
20178321
12.

Small-molecule inhibitors of the ERK signaling pathway: Towards novel anticancer therapeutics.

Yap JL, Worlikar S, MacKerell AD Jr, Shapiro P, Fletcher S.

ChemMedChem. 2011 Jan 3;6(1):38-48. doi: 10.1002/cmdc.201000354. Review. No abstract available.

13.

Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent.

Liu K, Guo TL, Hait NC, Allegood J, Parikh HI, Xu W, Kellogg GE, Grant S, Spiegel S, Zhang S.

PLoS One. 2013;8(2):e56471. doi: 10.1371/journal.pone.0056471. Epub 2013 Feb 20.

14.

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.

Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M, Smalley KS.

Clin Cancer Res. 2008 Jan 1;14(1):230-9. doi: 10.1158/1078-0432.CCR-07-1440.

15.

Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway.

Robert G, Jullian V, Jacquel A, Ginet C, Dufies M, Torino S, Pottier A, Peyrade F, Tartare-Deckert S, Bourdy G, Deharo E, Auberger P.

Oncotarget. 2012 Dec;3(12):1688-99.

16.

Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.

Manov I, Pollak Y, Broneshter R, Iancu TC.

FEBS J. 2011 Sep;278(18):3494-507. doi: 10.1111/j.1742-4658.2011.08271.x.

17.

The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2.

Polier G, Neumann J, Thuaud F, Ribeiro N, Gelhaus C, Schmidt H, Giaisi M, Köhler R, Müller WW, Proksch P, Leippe M, Janssen O, Désaubry L, Krammer PH, Li-Weber M.

Chem Biol. 2012 Sep 21;19(9):1093-104. doi: 10.1016/j.chembiol.2012.07.012.

18.

Synthesis and antibacterial and cytotoxic activities of new N-3 substituted thiazolidine-2,4-dione derivatives bearing the pyrazole moiety.

Desai NC, Satodiya HM, Kotadiya GM, Vaghani HV.

Arch Pharm (Weinheim). 2014 Jul;347(7):523-32. doi: 10.1002/ardp.201300466. Epub 2014 Apr 14.

PMID:
24729458
19.

Short waves-induced enhancement of proliferation of human chondrocytes: involvement of extracellular signal-regulated map-kinase (erk).

Wang JL, Chan RC, Cheng HH, Huang CJ, Lu YC, Chen IS, Liu SI, Hsu SS, Chang HT, Huang JK, Chen JS, Ho CM, Jan CR.

Clin Exp Pharmacol Physiol. 2007 Jul;34(7):581-5.

PMID:
17581212
20.

Stearoyl-CoA desaturase activity modulates the activation of epidermal growth factor receptor in human lung cancer cells.

Nashed M, Chisholm JW, Igal RA.

Exp Biol Med (Maywood). 2012 Sep;237(9):1007-17. Epub 2012 Sep 3.

PMID:
22946088

Supplemental Content

Support Center